Disruption of VEGFR signaling leading to developmental defects
The cardiovascular system is the first functional organ system to develop in the vertebrate
embryo, reflecting its critical role during normal development and pregnancy. This
Adverse Outcome Pathway focuses on the regulation and disruption of vasculogenesis-angiogenesis
during embryonic development via disruption of the Vascular Endothelial Growth Factor
(VEGF) signaling pathway. This pathway is a critical regulatory system for assembly
of embryonic blood vessels. Genetic studies have shown that perturbing the VEGF signaling
system can invoke varying degrees of adverse consequences, ranging from congenital
angiodysplasia to fetal malformations and embryolethality. This AOP is referred to
as AOP 43 in the Collaborative Adverse Outcome Pathway Wiki (AOP-Wiki).
Published on October 23, 2023
In series:OECD Series on Adverse Outcome Pathwaysview more titles